W P Miller1, L F Mantovani2, J Muzic3, J B Rykken4, R S Gawande4, T C Lund5, R M Shanley6, G V Raymond7, P J Orchard5, D R Nascene4. 1. From the Division of Pediatric Blood and Marrow Transplant (W.P.M., T.C.L., P.J.O.), Department of Pediatrics mill4991@umn.edu. 2. Division of Hematology and Oncology (L.F.M.), Department of Pediatrics, University of Sao Paulo, Sao Paulo, Brazil. 3. University of Minnesota Medical School (J.M.), Minneapolis, Minnesota. 4. Departments of Diagnostic Radiology (J.B.R., R.S.G., D.R.N.). 5. From the Division of Pediatric Blood and Marrow Transplant (W.P.M., T.C.L., P.J.O.), Department of Pediatrics. 6. Biostatistics Core (R.M.S.), Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota. 7. Neurology (G.V.R.), University of Minnesota Medical Center, Minneapolis, Minnesota.
Abstract
BACKGROUND AND PURPOSE: Outcomes following hematopoietic stem cell transplantation for higher risk childhood-onset cerebral adrenoleukodystrophy are variable. We explored whether a brain MR imaging gadolinium intensity scoring system improves prediction of neurologic outcome. MATERIALS AND METHODS: We developed a 4-point scale of gadolinium intensity relative to the choroid plexus: 0 = no enhancement; 1 = hypointense; 2 = isointense; 3 = hyperintense. The interobserver concordance of the scale was assessed on 30 randomly chosen studies. Scores were generated for 64 evaluable patients and compared with CSF chitotriosidase levels, a known inflammatory marker correlating with outcomes following transplantation. For 25 evaluable higher risk patients (Loes ≥10), the gadolinium intensity score was compared with longer term posttransplantation clinical change. RESULTS: The gadolinium intensity scoring system showed good interobserver reproducibility (κ = 0.72). Of 64 evaluable boys, the score positively correlated with average concomitant CSF chitotriosidase activity in nanograms/milliliter/hour: 0: 2717, n = 5; 1: 3218, n = 13; 2: 6497, n = 23; and 3: 12,030, n = 23 (P < .01). For 25 evaluable higher risk patients, more intense pretransplantation brain MR imaging gadolinium enhancement predicted greater average loss on the adrenoleukodystrophy neurologic function scale following transplantation: 0/1: adrenoleukodystrophy neurologic function scale score difference = 4.3, n = 7; 2/3: adrenoleukodystrophy neurologic function scale score difference = 10.4, n = 18 (P = .05). CONCLUSIONS: Gadolinium enhancement intensity on brain MR imaging can be scored simply and reproducibly for cerebral adrenoleukodystrophy. The enhancement score significantly correlates with chitotriosidase. In boys with higher risk cerebral disease (Loes ≥10), the enhancement score itself predicts neurologic outcome following treatment. Such data may help guide treatment decisions for clinicians and families.
BACKGROUND AND PURPOSE: Outcomes following hematopoietic stem cell transplantation for higher risk childhood-onset cerebral adrenoleukodystrophy are variable. We explored whether a brain MR imaging gadolinium intensity scoring system improves prediction of neurologic outcome. MATERIALS AND METHODS: We developed a 4-point scale of gadolinium intensity relative to the choroid plexus: 0 = no enhancement; 1 = hypointense; 2 = isointense; 3 = hyperintense. The interobserver concordance of the scale was assessed on 30 randomly chosen studies. Scores were generated for 64 evaluable patients and compared with CSF chitotriosidase levels, a known inflammatory marker correlating with outcomes following transplantation. For 25 evaluable higher risk patients (Loes ≥10), the gadolinium intensity score was compared with longer term posttransplantation clinical change. RESULTS: The gadolinium intensity scoring system showed good interobserver reproducibility (κ = 0.72). Of 64 evaluable boys, the score positively correlated with average concomitant CSF chitotriosidase activity in nanograms/milliliter/hour: 0: 2717, n = 5; 1: 3218, n = 13; 2: 6497, n = 23; and 3: 12,030, n = 23 (P < .01). For 25 evaluable higher risk patients, more intense pretransplantation brain MR imaging gadolinium enhancement predicted greater average loss on the adrenoleukodystrophy neurologic function scale following transplantation: 0/1: adrenoleukodystrophy neurologic function scale score difference = 4.3, n = 7; 2/3: adrenoleukodystrophy neurologic function scale score difference = 10.4, n = 18 (P = .05). CONCLUSIONS:Gadolinium enhancement intensity on brain MR imaging can be scored simply and reproducibly for cerebral adrenoleukodystrophy. The enhancement score significantly correlates with chitotriosidase. In boys with higher risk cerebral disease (Loes ≥10), the enhancement score itself predicts neurologic outcome following treatment. Such data may help guide treatment decisions for clinicians and families.
Authors: Weston P Miller; Steven M Rothman; David Nascene; Teresa Kivisto; Todd E DeFor; Richard S Ziegler; Julie Eisengart; Kara Leiser; Gerald Raymond; Troy C Lund; Jakub Tolar; Paul J Orchard Journal: Blood Date: 2011-05-17 Impact factor: 22.113
Authors: James M Powers; Zhengtong Pei; Ann K Heinzer; Rebecca Deering; Ann B Moser; Hugo W Moser; Paul A Watkins; Kirby D Smith Journal: J Neuropathol Exp Neurol Date: 2005-12 Impact factor: 3.685
Authors: Charles Peters; Lawrence R Charnas; Ye Tan; Richard S Ziegler; Elsa G Shapiro; Todd DeFor; Satkiran S Grewal; Paul J Orchard; Susan L Abel; Anne I Goldman; Norma K C Ramsay; Kathryn E Dusenbery; Daniel J Loes; Lawrence A Lockman; Shunichi Kato; Patrick R Aubourg; Hugo W Moser; William Krivit Journal: Blood Date: 2004-04-08 Impact factor: 22.113
Authors: D J Loes; S Hite; H Moser; A E Stillman; E Shapiro; L Lockman; R E Latchaw; W Krivit Journal: AJNR Am J Neuroradiol Date: 1994-10 Impact factor: 3.825
Authors: Paul J Orchard; Troy Lund; Wes Miller; Steven M Rothman; Gerald Raymond; David Nascene; Lisa Basso; James Cloyd; Jakub Tolar Journal: J Neuroinflammation Date: 2011-10-20 Impact factor: 8.322
Authors: Paul J Orchard; David R Nascene; Weston P Miller; Ashish Gupta; Dan Kenney-Jung; Troy C Lund Journal: Blood Date: 2019-01-11 Impact factor: 22.113
Authors: Elizabeth I Pierpont; Julie B Eisengart; Ryan Shanley; David Nascene; Gerald V Raymond; Elsa G Shapiro; Rich S Ziegler; Paul J Orchard; Weston P Miller Journal: JAMA Neurol Date: 2017-06-01 Impact factor: 18.302
Authors: Leyla A Taghizadeh; Carina J King; David R Nascene; Ashish O Gupta; Paul J Orchard; LeeAnn Higgins; Todd W Markowski; Erin E Nolan; Justin W Furcich; Troy C Lund Journal: Sci Rep Date: 2022-05-14 Impact factor: 4.996
Authors: A M McKinney; J Benson; D R Nascene; J Eisengart; M B Salmela; D J Loes; L Zhang; K Patel; G V Raymond; W P Miller Journal: AJNR Am J Neuroradiol Date: 2016-04-14 Impact factor: 3.825
Authors: Arne Lauer; Xiao Da; Mikkel Bo Hansen; Gregoire Boulouis; Yangming Ou; Xuezhu Cai; Afonso Liberato Celso Pedrotti; Jayashree Kalpathy-Cramer; Paul Caruso; Douglas L Hayden; Natalia Rost; Kim Mouridsen; Florian S Eichler; Bruce Rosen; Patricia L Musolino Journal: Brain Date: 2017-12-01 Impact factor: 13.501
Authors: Paul J Orchard; Todd W Markowski; LeeAnn Higgins; Gerald V Raymond; David R Nascene; Weston P Miller; Elizabeth I Pierpont; Troy C Lund Journal: Sci Rep Date: 2019-05-27 Impact factor: 4.379
Authors: Isabelle Weinhofer; Paulus Rommer; Bettina Zierfuss; Patrick Altmann; Martha Foiani; Amanda Heslegrave; Henrik Zetterberg; Andreas Gleiss; Patricia L Musolino; Yi Gong; Sonja Forss-Petter; Thomas Berger; Florian Eichler; Patrick Aubourg; Wolfgang Köhler; Johannes Berger Journal: Nat Commun Date: 2021-03-22 Impact factor: 14.919